| Literature DB >> 30993888 |
Lei Xu1,2, Yang Li3, Lixing Zhou4, Robert Gregory Dorfman5, Li Liu1, Rui Cai1, Chenfei Jiang2, Dehua Tang2, Yuming Wang2, Xiaoping Zou1,2, Lei Wang1,2, Mingming Zhang1,2.
Abstract
Cholangiocarcinoma (CCA) is an extremely invasive malignancy with late diagnosis and unfavorable prognosis. Surgery and chemotherapy are still not effective in improving outcomes in CCA patients. It is crucial to explore a novel therapeutic target for treating CCA. An NAD-dependent deacetylase also known as Sirtuin-3 (SIRT3) has been shown to regulate cellular metabolism in various cancers dynamically. However, the biological function of SIRT3 in CCA remains unclear. In this study, bioinformatics analyses were performed to identify the differentially expressed genes and pathways enriched. CCA samples were collected for immunohistochemical analysis. Three human CCA cell lines (HuCCT1, RBE, and HCCC9810) were used to explore the molecular mechanism of SIRT3 regulation of metabolic reprogramming and malignant behavior in CCA. A CCA xenograft model was then established for further validation in vivo. The data showed that SIRT3 expression was decreased and glycolysis was enhanced in CCA. Similar metabolic reprogramming was also observed in SIRT3 knockout mice. Furthermore, we demonstrated that SIRT3 could play an anti-Warburg effect by inhibiting the hypoxia-inducible factor-1α (HIF1α)/pyruvate dehydrogenase kinase 1 (PDK1)/pyruvate dehydrogenase (PDHA1) pathway in CCA cells. CCA cell proliferation and apoptosis were regulated by SIRT3-mediated metabolic reprogramming. These findings were further confirmed in CCA clinical samples and the xenograft model. Collectively, this study suggests that in the inhibition of CCA progression, SIRT3 acts through an anti-Warburg effect on the downstream pathway HIF1α/PDK1/PDHA1.Entities:
Keywords: Cholangiocarcinoma; Metabolic reprogramming; SIRT3; Warburg effect
Mesh:
Substances:
Year: 2019 PMID: 30993888 PMCID: PMC6536927 DOI: 10.1002/cam4.2089
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
Figure 1Glycolysis is enhanced in CCA. (A) The differentially expressed genes (DEGs) we screened out in CCA by investigating TCGA database and the most relevant DEGs associated with glucose homeostasis and gluconeogenesis were confirmed through functional enrichment analysis. (B) Tumor tissues and adjacent normal tissues from four CCA patients were collected and lysed, and the concentrations of the metabolites in clinical samples were measured by mass spectrometry (MS). Red indicates high concentration and blue indicates low concentration. (C) A schematic diagram of glucose metabolism suggests an increase in the concentrations of glutamate and lactate and a decrease in the pyruvate concentration. (D) The oxygen consumption rates (OCR) of three different CCA cells and normal intrahepatic biliary epithelial cells (HIBEpiC) were detected at different time points. The OCR under treatments with oligomycin, carbonyl cyanide‐m‐chlorophenylhydrazone (FCCP), and antimycin A/rotenone were detected. (E) Complex1 activity statistics for CCA cells and normal intrahepatic biliary epithelial cells (HIBEpiC). (F) Expression of glucose metabolism‐related enzymes in CCA cells and normal intrahepatic biliary epithelial cells (HIBEpiC). (G) Expression of glucose metabolism‐related enzymes in CCA clinical samples (n = 6). Data represent the mean ± SEM, n ≥ 3. *P < 0.05; **P < 0.01.
Figure 2Glycolysis is enhanced in SIRT3 knockout mice. (A) The extracellular glucose levels were detected in MIBECs from control mice or SIRT3 knockout mice. (B) The intracellular glucose uptake was measured in MIBECs from control mice or SIRT3 knockout mice. (C) Lactate output was analyzed in MIBECs from control mice or SIRT3 knockout mice. (D) Complex1 activity was detected in MIBECs from control mice or SIRT3 knockout mice. (E) The OCR of MIBECs from control mice or SIRT3 knockout mice was detected at different time points. (F) MIBECs proliferation from control mice or SIRT3 knockout mice was analyzed via CCK‐8 assay. (G) The cytoplasm and membrane expression of GLUT1 in MIBECs from wild‐type and SIRT3 knockout mice. (H) The expression of HIF1α and SIRT3 in MIBECs from wild‐type and SIRT3 knockout mice. Data represent the mean ± SEM, n ≥ 3. *P < 0.05; **P < 0.01.
Figure 3SIRT3 regulates glucose metabolism in CCA cells through the HIF1α/PDK1/PDHA1 pathway. (A) CCA cells in the case of hypoxia or siSIRT3 were collected and lysed, the concentrations of the metabolites in the clinical samples were measured by MS (B) The OCR of CCA cells were detected at different time points following transfection with siSIRT3 and SIRT3‐Flag. (C) Relative ROS levels in HuCCT1 (left) and RBE (right) cells treated with different concentrations of Honokiol for 48 h. (D) Relative ROS levels in HuCCT1 (left) and RBE (right) cells treated with siSIRT3, BX‐795 (50 μmol/L for 48 h), or a combination of siSIRT3 and BX‐795. (E) The key proteins associated with HIF1α/PDK1/PDHA1 in HuCCT1 and RBE cells were assessed following treatment with 50 μmol/L Honokiol for 48 h (left), transfection with the SIRT3 overexpression vector (middle) or siSIRT3 (right). (F) The key proteins associated with HIF1α/PDK1/PDHA1 in HuCCT1 and RBE cells were evaluated following transfection with HIF1α‐Flag (left) or siHIF1α (right). Data represent the mean ± SEM, n ≥ 3. *P < 0.05; **P < 0.01.
Figure 4PDK1 is a key downstream molecule of SIRT3 regulating CCA cell proliferation and apoptosis. (A) Apoptotic HuCCT1 (left) and RBE (right) cells were measured via flow cytometry with different concentrations of Honokiol for 48 h. (B) Apoptotic HuCCT1 (left) and RBE (right) cells treated with siSIRT3, BX‐795 (50 μmol/L for 48 h), or a combination of both were analyzed via flow cytometry. (C) HuCCT1 (left) and RBE (right) cells were treated with 10 μmol/L Honokiol for 48 h; cell colonies were quantified after 14 d. (D) HuCCT1 (left) and RBE (right) cells were transfected with siSIRT3 or the SIRT3 overexpression vector; cell colonies were quantified after 14 d. (E) HuCCT1 (left) and RBE (right) cells were treated with siSIRT3, BX‐795 (50 μmol/L for 48 h), or a combination of both; cell colonies were quantified after 14 d. (F) HuCCT1 (left) and RBE (right) cell proliferation was analyzed via the CCK‐8 assay following treatment with different concentrations of Honokiol for 48 h. (G) HuCCT1 (left) and RBE (right) cell proliferation was analyzed via the CCK‐8 assay following transfection with siSIRT3. Data represent the mean ± SEM, n ≥ 3. *P < 0.05; **P < 0.01
Figure 5SIRT3 inhibits tumor proliferation via the HIF1α/PDK1/PDHA1 pathway in CCA clinical samples and xenograft model. (A) SIRT3, HIF1α, and p‐PDHA1 protein levels in CCA tumor and adjacent tissues (n = 20) were detected (left) and quantified (right) by immunohistochemistry. The magnification is 400x. Scale bars, 50 μm. (B) Honokiol suppresses CCA cell xenograft tumor growth in nude mice. Tumors were photographed after all animals were sacrificed (n = 10). (C) The body weights of nude mice inoculated subcutaneously with HuCCT1 cells (n = 10). (D) The volume of xenograft tumors (n = 10). (E) Xenograft tumors were isolated and lysed from sacrificed nude mice. The expression levels of SIRT3, HIF1α, PDK1, and p‐PDHA1 were detected by western blotting. Data represent the mean ± SEM, n ≥ 3. *P < 0.05; **P < 0.01; The staining score for each CCA sample was calculated by multiplying the staining intensity by the staining percentage, and the value range was between 0 and 12